Drug major Cipla slashed the price of three cancer drugs. In May YK Hamied Chairman and managing director of Cipla had promised that to continue slashing the price of its cancer drugs. The new drugs cost 50-64% less than its older prices. Lung cancer drug Erlocip will cost Rs 9900 (earlier Rs 27000) while breast cancer treatment drug Docetax will cost Rs 1650 instead of Rs 3300. Incidentally Erlocip is a replicated version of Roche s Tarceva. Last month Cipla won a case against Roche who had dragged the Indian pharma company to court for infringing patent rights. Capegard another
